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Abstract
Background: Targeted analgesic dietary interventions are a promising strategy for alleviating pain and improving
quality of life in patients with persistent pain syndromes, such as chronic daily headache (CDH). High intakes of the
omega-6 (n-6) polyunsaturated fatty acids (PUFAs), linoleic acid (LA) and arachidonic acid (AA) may promote
physical pain by increasing the abundance, and subsequent metabolism, of LA and AA in immune and nervous
system tissues. Here we describe methodology for an ongoing randomized clinical trial comparing the metabolic
and clinical effects of a low n-6, average n-3 PUFA diet, to the effects of a low n-6 plus high n-3 PUFA diet, in
patients with CDH. Our primary aim is to determine if: A) both diets reduce n-6 PUFAs in plasma and erythrocyte
lipid pools, compared to baseline; and B) the low n-6 plus high n-3 diet produces a greater decline in n-6 PUFAs,
compared to the low n-6 diet alone. Secondary clinical outcomes include headache-specific quality-of-life, and
headache frequency and intensity.
Methods: Adults meeting the International Classification of Headache Disorders criteria for CDH are included. After
a 6-week baseline phase, participants are randomized to a low n-6 diet, or a low n-6 plus high n-3 diet, for 12
weeks. Foods meeting nutrient intake targets are provided for 2 meals and 2 snacks per day. A research dietitian
provides intensive dietary counseling at 2-week intervals. Web-based intervention materials complement dietitian
advice. Blood and clinical outcome data are collected every 4 weeks.
Results: Subject recruitment and retention has been excellent; 35 of 40 randomized participants completed the
12-week intervention. Preliminary blinded analysis of composite data from the first 20 participants found significant
reductions in erythrocyte n-6 LA, AA and %n-6 in HUFA, and increases in n-3 EPA, DHA and the omega-3 index,
indicating adherence.
Trial Registration: ClinicalTrials.gov (NCT01157208)
Background
Targeted analgesic dietary interventions are a novel stra-
tegic approach with promise for alleviating pain and
improving quality of life in patients with persistent pain
syndromes. Chronic Daily Headache (CDH), defined as
presence of headaches lasting 4 hours or more for 15 or
more days per month over at least 3 months, is a
debilitating pain syndrome that affects 4 to 5% of the
adult population in the US, roughly 10 million Ameri-
cans [1-6]. Loss of work and medical expenses add up
to billions of dollars per year [7,8]. Chronic episodic
migraines, chronic tension-type headaches, and other
primary headaches may evolve into CDH, which is
believed to represent a final common pathway for sev-
eral distinct headache types [9,10]. CDH accounts for
up to 40% of patients presenting to headache specialty
clinics. Patients with CDH often receive only limited
benefit from conventional medical management.
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Conventional treatments rely heavily on medications
that may provide limited or transient relief, target symp-
toms rather than underlying causes of pain, and are
associated with significant side effects and costs [11-15].
Paradoxically, headache medications may facilitate the
transformation of intermittent headaches to more fre-
quent and disabling chronic daily headaches [16]. More-
over, medication side effects are often significant and
include not only medication overuse syndromes, but
also weight gain, fatigue, and depression, among many
other side effects [12,13].
The Role of Diet in Chronic Pain
Multiple metabolic pathways that are important in pain
processing converge at the level of omega-6 (n-6) ara-
chidonic acid (AA) metabolism. AA can directly potenti-
ate N-methyl-d-aspartate (NMDA) receptor currents
[17-19]. AA is also the precursor to a wide array of neu-
roactive [20-23] and vasoactive [24-27] compounds that
are relevant to pain processing. We hypothesized that
the overabundance and/or hyperactive metabolism of n-
6 AA in nervous and immune system tissues serve as a
fundamental metabolic basis for central pain sensitiza-
tion and human physical pain [28].
Certain dietary patterns may promote physical pain by
increasing the amount and/or subsequent metabolism of
AA in nervous and immune system tissues [28]. Humans
cannot synthesize AA de novo. Tissue phospholipid con-
centrations of AA (PL-AA) are dependent on dietary
intake of 1) n-6 AA [29]; 2) a precursor to AA, linoleic
acid (LA) [30]; and 3) competing fatty acids, including n-
3 eicosapentaenoic acid (EPA) and docosahexaenoic acid
(DHA) [31]. Competition continues as n-6 AA and n-3
EPA + DHA act as rival substrates for enzymatic cleavage
and conversion into bioactive compounds (e.g. eicosa-
noids, docosanoids, endocannabinoids, and endovanil-
loids). Thus, restricted n-6 consumption and/or
increased intake of competing fatty acids may diminish
the consequences of elevated tissue concentrations of AA
and/or the synthesis of AA metabolites. Restricted n-6
consumption and/or increased n-3 EPA + DHA intake
may also increase the abundance and subsequent meta-
bolism of EPA and DHA derivatives with analgesic prop-
erties (e.g. resolvins, neuroprotectins) [32].
To test this hypothesis, we designed a 12-week, con-
trolled dietary trial in 76 participants with CDH rando-
mized into 1 of 2 arms: 1) usual medical care plus a low
n-6 diet with <2.0 percent of energy (en%) as linoleic
acid (LA), <60 mg/d of AA, and average US n-3 intake
(Table 1); or 2) usual medical care plus a low n-6, high
n-3 diet with <2.0 en% as LA, 1.8 en% as alpha-linolenic
acid (ALA) and >1.5 g/d of EPA+DHA (Table 1).
In this paper, we describe the design of the ongoing
dietary trial, and report preliminary compliance data, as
indicated by reductions in n-6 LA, AA and the percen-
tage of n-6 highly unsaturated fatty acids (HUFA) in
total HUFA (%n-6 in HUFA), and increases in EPA,
DHA and omega-3 index in erythrocyte membranes.
Implementation strategies are described along with
methods for maintaining compliance and ensuring opti-
mal data collection.
Methods
Study Design
The study is a randomized trial comparing 2 dietary
interventions designed to reduce tissue content of AA
and total n-6 HUFA, and testing the impact of these
interventions on alteration of the phenotypic expression
of CDH. Figure 1 illustrates the overall design and sub-
ject flow through the study. Study procedures and con-
sent forms were reviewed and approved by the
Institutional Review Board and the Clinical and Transla-
tional Research Center (CTRC) of the University of
North Carolina (UNC).
Eligibility
Patients referred to the study are screened for CDH
using the 2004 International Classification of Headache
Disorders (ICHD-II) criteria, and are evaluated for elig-
ibility using the inclusion and exclusion criteria listed in
Table 2. Our target is 76 participants qualifying for ran-
domization. Based on our experience with attrition rates
in headache studies, we expect at least 80% of the head-
ache sufferers enrolled in the trial to complete the
intervention.
Table 1 Nutrient intake targets for a study of exploratory
analgesic dietary interventions for chronic daily
headache, May 2010*
Nutrient Low
omega-6
diet
Low omega-6 +
High omega-3
diet
Total protein 18 18
Total carbohydrate 50 50
Total fat 32 32
Trans fatty acids <0.5 <0.5
Total saturated fat 13 13
Total monounsaturated fatty acids
(MUFA)
16 14
Total polyunsaturated fatty acids
(PUFA)
2.5 4.5
Linoleic acid, 18:2n-6 (LA) <2.0 <2.0
Arachidonic acid, 20:4n-6 (AA) 60 mg 150 mg
Alpha-linolenic acid, 18:3n-3 (ALA) 0.6 1.8
Eicosapentaenoic acid, 20:5n-3 (EPA) +
Docosahexaenoic acid, 22:6n-3 (DHA)
150 mg 1500-2000 mg
*All values are expressed as % of energy except AA and EPA+DHA (mg per
day)
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Telephone screen for eligibility expected (n = 200)
Ineligible: expect to exclude (n = 80)
Headache characteristics 
Other medical exclusions 
No physician 
Scheduling difficulties
First confirmation of eligibility (n = 120)
Baseline study visit with neurologist (PI)
Consent for study, begin baseline diary collection
Baseline instruments (HIT-6, SF-12, BSI-18)
Expect to exclude (n = 30 )
Headache characteristics
Second confirmation of eligibility (n= 90 )
Baseline diaries reviewed
Unstable co-morbid conditions
Expect to exclude (n = 20 )
Failure to keep diaries 
Headache characteristics 
Random allocation to one of two diets
Expect to randomize (n = 70)
Baseline blood fatty acid acids and metabolic biomarkers
Pre-intervention Instruments (HIT-6, SF-12, MIDAS, BSI-18)
Baseline dietary intake assessment
Other intervening problems 
Low n-6 diet 
Dietary counseling Q2 wks 
Study foods supplied Q2 wks 
Daily Headache Diary
Dietary adherence assessments
Low n-6, high n-3 diet
Dietary counseling Q2 wks
Study foods supplied Q2 wks
Daily Headache Diary
Dietary adherence assessments
Post-intervention assessment
Week 12 blood collection 
Di HIT 6 MIDAS SF 12 BSI 18
Post-intervention assessment
Week 12 blood collection 
Di HIT 6 MIDAS SF 12 BSI 18
Week 4 blood collection
Week 8 blood collection
Week 4 blood collection
Week 8 blood collection
etary assessment; - , , - , -
Nutritional/metabolic biomarker analyses
Expected withdrawal = 3
ITT analysis of data
Expected n = 32
ITT analysis of data
Expected n = 32
etary assessment; - , , - , -
Nutritional/metabolic biomarker analyses
Expected withdrawal = 3
Figure 1 Study flow diagram for the exploratory analgesic dietary intervention for chronic daily headache, May 2010. Abbreviations:
HUFA, highly-unsaturated fatty acid; HIT-6, Headache Impact Test; MIDAS, Migraine Disability Assessment Questionnaire; BSI-18, Brief Symptom
Inventory.
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Recruitment
Participants are recruited from the following sources: 1)
University of North Carolina (UNC) Headache Clinic; 2)
multiple area neurology practices; 3) broadcast email to
UNC employees and students; 4) brochures and flyers at
UNC clinics and research centers.
Screening, consent, and enrollment procedures
Interested individuals contact the research staff for a tel-
ephone screening interview. If the screening process
identifies them as potentially eligible, the individuals
meet with the study staff for consenting, a baseline neu-
rological assessment, and completion of baseline mea-
sures. The study neurologist confirms the diagnosis of
CDH and excludes from the study those individuals
with other medical problems that could put the partici-
pant at risk or confound the study results. Individuals
may also be excluded if they are unwilling or unable to
commit to a 12-week dietary intervention. Excluded
patients are referred back to their physicians for further
medical management. Enrolled participants continue to
be cared for by their personal physicians, but are asked
to avoid changes in over-the-counter medications, diet-
ary supplements, and non-pharmacologic treatments for
headache during the course of the study. Medication
changes for headache management by the treating phy-
sician are allowed and documented.
Baseline Period
Eligible participants are instructed in the maintenance of
a daily online headache diary for 6 consecutive weeks
while continuing usual care. After they have completed
4 weeks of diaries, their entries are reviewed with the
study neurologist to determine eligibility for the treat-
ment phase of the study. Eligibility consists of comple-
tion of at least 80% of headache diaries and report of at
least 15 headache days per month. Each headache day
must have a minimum of 4 consecutive hours of
headache. Eligible participants are scheduled to visit the
research dietitian for 7 consultations over the course of
the 12-week intervention. They are asked to continue
their headache diaries for the full 18-week duration of
the study.
Randomization
At the first treatment visit, study participants are rando-
mized to 1 of 2 diets, a low n-6 diet, or a low n-6 plus
high n-3 diet (Figure 1 and Table 1), to be maintained
for 12 consecutive weeks. Randomization employs a
computer algorithm using a random number sequence
to generate a permuted block of 4-8 subjects, ensuring
equal numbers of participants in each arm of the study
[33]. The program, accessed only through an on-line
interface by the study dietitian, also documents treat-
ment assignment in an un-editable form with a date
stamp.
Interventions
Participants in both intervention arms receive: 1) tar-
geted and tailored dietitian-administered counseling at
the CTRC; 2) access to an intervention-specific website;
and 3) a continuous supply of food items with precisely
quantified fatty acid compositions formulated to meet
nutrient intake targets. Participants meet with the
research dietitian approximately every 14 days through-
out the 12-week dietary intervention to receive diet edu-
cation, a 2-week supply of research foods, and a dietary
adherence assessment. Meal plans and recipes that meet
the nutrient intake targets are provided, as well as speci-
fic instructions on how to meet the diet targets and
what foods to purchase in addition to those provided by
the study. Study-provided foods are selected based on
fatty acid analysis completed by the Section on Nutri-
tional Neurochemistry, Laboratory of Membrane Bio-
chemistry and Biophysics, NIAAA/NIH. Research foods
are procured and prepared by the Nutrition Research
Table 2 Eligibility of subjects for participation in the study of dietary interventions for chronic daily headache, May
2010
All subjects are evaluated by a neurologist prior to enrollment
Inclusion Criteria Exclusion Criteria
• Subjects >18 years of age • Marked depression, anxiety or psychosis
• Either gender
• Meets 2004 ICHD-II* criteria for Chronic Daily Headache
• Headache frequency days/month: > 15
• Headache history: > 2 years
Includes: Chronic migraine, transformed episodic migraine into CDH, chronic
tension-type headache and persistent daily headache
• Willing to complete daily diary for 6 weeks
• Able to attend 12 weekly treatments
• Under care of physician for headaches
• Able to read and communicate in English
• Pregnancy or anticipated pregnancy
• Active treatment for a major medical illness, such as malignancy,
autoimmune or immune deficiency disorder
• History of significant head trauma or head/neck surgery within
the past 2 years
• History of subarachnoid or intra-cerebral hemorrhage or chronic
subdural hematoma
• History of clotting disorder
• History of systemic infection such as meningitis or encephalitis
• History of vasculitis or intracranial mass
• Cognitive dysfunction that would prevent informed consent
*International Classification of Headache Disorders, defined by expert members of the International Headache Society
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and Metabolism Core of the Clinical and Translational
Research Center at UNC, which is supported in part by
grant UL1RR025747 from the National Center for
Research Resources, National Institutes of Health.
Participants in both diet groups are educated on how
to limit LA and AA in their diets. Because most avail-
able US oils contain substantial amounts of LA, partici-
pants are provided with, and instructed to use, only low
LA oils and fat sources (e.g. macadamia nut oil, coconut
oil, low-LA olive oil, butter, fat-free mayonnaise, speci-
fied salad dressings). Nutrient analysis performed on
numerous brands of each of the above oils and fat
sources ensured the selection of those with the lowest
LA content.
Participants randomized to the low n-6 plus average
n-3 diet group are instructed to reduce their intake of
AA by restricting consumption of egg yolks, organ
meats, meats, and certain fish. They are asked to eat up
to 2 vegetarian meals per day, and up to 1 meal per day
that includes very lean (low n-3) fish or shellfish and/or
egg whites. Study foods provided to low n-6 dieters
include several types of canned beans, frozen lean sea-
food (e.g. shrimp, grouper, cod, very low-fat chunk light
tuna), and low-fat turkey slices, chosen on the basis of
nutrient analyses to achieve the lowest amounts of n-3
EPA+DHA and n-6 AA.
Study participants randomized to the low n-6 plus
high n-3 diet are instructed to consume 14 g of ground
flaxseed each day, to reach the nutrient intake target for
n-3 ALA (Table 1). They receive ground flaxseed or pre-
pared flaxseed products to include granola, muffins,
granola bars and bean dip. To reach EPA and DHA
nutrient intake targets, the low n-6 plus high n-3 dieters
are counseled to consume 1-2, 4 oz servings of fatty fish
per day. They are provided with high n-3 canned tuna,
canned salmon, frozen salmon fillets, frozen trout and
sardines. Nutrient analysis of numerous seafood sources
enabled selection of foods with the highest amounts of
n-3 EPA+DHA.
Participants in both diet groups are given breads,
crackers, tortillas, popcorn, yogurt, string cheese, frozen
fruits and vegetables, beans, and prepared vegetarian
chili. These carefully-selected study foods displace high
LA foods and facilitate adherence with study diets.
Web-based intervention materials complement and rein-
force dietitian advice. Diet education materials include:
1) Diet Guidelines; 2) Seven-day Meal Plan; 3) Grocery
Shopping Guides; 4) Dining Out Guide; 5) Food Lists;
and 6) more than 50 recipes that either utilize the study
provided foods or meet study guidelines.
Participants complete self-reported outcome assess-
ments at baseline, at their first intervention visit, and at
the end of the intervention. They have blood drawn for
biomarkers at the first intervention visit (Week 6), and
again at weeks 10, 14, and 18. The research staff vali-
dates data through weekly contact with participants.
Masking
Because of the nature of the interventions, the research
dietitian cannot be masked to treatment condition.
Similarly, participants are aware of the foods included in
their diets. However, participants do not have access to
information about the other diet. In addition, steps are
taken to ensure that credibility of both dietary interven-
tions is maintained. A questionnaire assessing the cred-
ibility of both diets as an intervention for headache is
administered after the first visit with the dietitian. All
investigators except the research dietitian are masked to
treatment assignment. Similarly, participants’ personal
physicians are masked to treatment assignment.
Remuneration
Participants receive 12 weeks of dietary treatment at no
cost. During these 12 weeks, participants receive food for
2 meals and 2 snacks per day, supplied every other week
by the CTRC research kitchen. Participants completing
the study receive $145 in compensation in addition to
costs of mileage and parking of up to $13 per visit.
Outcome measures and study instruments
Primary Outcomes
The primary outcome (Aim 1) is the change in percen-
tage of n-6 in HUFA in total HUFA (%n-6 in HUFA) in
plasma and erythrocyte lipid pools, from pre-interven-
tion (Week 6 - end of baseline phase) to post-interven-
tion (Week 18). For determination of the %n-6 in
HUFA, fatty acids that are at least 20 carbons in length
with 3 more double bonds are considered to be HUFAs.
The equation for calculation of %n-6 in HUFA is 100 ×
(20:3n-6 + 20:4n-6 + 22:4n-6 + 22:5n-6)/(20:5n-3 +
22:5n-3 + 22:6n-3 + 20:3n-6 + 20:4n-6 + 22:4n-6 +
22:5n-6 + 20:3n-9). For Aim 2, we examine the rate of
change in %n-6 in HUFA over the 12 weeks of the
intervention as measured at Study Week 6, Week 10,
Week 14, and Week 18 (Weeks 0, 4, 8, and 12 of the
intervention phase).
Secondary Laboratory Outcomes
Secondary laboratory outcomes include individual n-6
and n-3 fatty acids in plasma and erythrocyte lipid
pools, including n-6 linoleic acid (18:2n-6) and AA, as
well as n-3 EPA and DHA. Lipid mediators derived
from n-6 AA, EPA and DHA (e.g. eicosanoids, docosa-
noids), and mediators that may be indirectly influenced
by n-6 and n-3 HUFA status (e.g. cytokines, pro-inflam-
matory enzymes, substance P), will be measured at
study completion.
Changes in inflammatory gene expression in peripheral
blood mononuclear cells (PBMCs) will be assessed in an
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additional pilot study. We will test: (1) the effects of the
low n-6 diet compared to baseline dietary conditions
(gene expression before the dietary intervention); (2) the
effects of the low n-6 + high n-3 diet compared to base-
line; and (3) the effects of the low n-6 versus the low n-6
+ high n-3 diet compared to baseline. PBMCs are isolated
from whole blood and RNA will be extracted utilizing
Qiagen RNeasy Micro Kit (Valencia, CA). The RNA yield
will be quantified with Nanodrop ND 1000 spectrophot-
ometer (Nanodrop Technologies, Wilmington, DE), and
integrity will be measured with an Agilent 2100 Bioanaly-
zer with RNA 6000 Nano chips (Santa Clara, CA). The
expression of 84 key genes involved in the inflammatory
response will be assessed using the Human Inflammatory
Cytokines & Receptors RT² Profiler PCR Array (SA Bios-
ciences, Frederick, MD).
Clinical outcomes
Although this study is not powered to assess changes in
clinical endpoints, we are measuring the following out-
comes in preparation for a larger, fully powered trial of
clinical efficacy (Table 3):
(1) Headache frequency and intensity, medication
use, cost of medication, and health care utilization,
all collected by self-report in a detailed daily head-
ache diary [34]. The diary, available to participants
on a secure website, collects data on headache inten-
sity (none, mild, moderate, severe) and associated
aura for every hour of the day and night.
(2) Headache-specific quality-of-life, measured
through the Headache Impact Test (HIT-6) [35] at
the time of randomization and after completion of
the intervention. The HIT-6, with good internal
reliability [36], covers functioning relevant to head-
ache-related disability: pain, social functioning, role
functioning, vitality, cognitive functioning, and psy-
chological distress. A decrease of 2.3 HIT points
(95% CI, 0.3 to 4.3) over 6 weeks among patients
with chronic headache corresponds to a “somewhat
better” self-reported rating on a global clinical
change scale [36].
(3) Headache-related disability, measured with the
Migraine Disability Assessment Questionnaire
(MIDAS) [37,38] pre-randomization and at the end
of the 12-week intervention. Derived from the Head-
ache Impact Test, MIDAS is a 7-item questionnaire
that assesses the number of days during the previous
3 months that respondents missed work or school,
experienced decreased productivity at work or home,
or missed social engagements because of headaches
[38]. Test-retest reliability and internal consistency
are acceptable (r2: 0.67-0.73; alpha = 0.83) [39].
(4) General health-related quality-of-life (SF-12) is
measured with a shorter version of the popular
Medical Outcomes Study Short Form Health Survey
(SF-36) that yields a summary score for mental com-
ponents and physical components [40]. The SF-12
was found to be reliable, valid, and responsive to
change in a population of chronic-back-pain patients
[41], and has been employed in migraine research
[42].
(5) General psychological distress as measured with
the Brief Symptom Inventory (BSI-18), a short (18-
item) version of the Symptom Checklist-90-R (SCL-
90-R) [43]. Subjects are asked to rate how much
Table 3 Summary of measures and timing of
administration for exploratory analgesic dietary
intervention for chronic daily headache as of May 2010
Variable or Instrument Usual
Care - UC
Weeks 0 to 6
UC + Diet
Weeks 6 to 18
Primary outcome
Headache QOL - HIT-6 § Week 0, Week 6 Week 18
Secondary outcomes
Headache Diary: Frequency Daily Daily
Perceived clinical change Week 0, Week 6 Week 18
Headache disability - MIDAS# Week 6 Week 18
Headache Diary: Intensity/
Duration
Daily Daily
Headache Diary: Sleep
Duration
Daily Daily
Headache Diary: Medication
Use/Cost
Daily Daily
Headache Diary: Health care
visits
Daily Daily
Satisfaction with care Week 0, Week 6 Week 18
Psychological health: BSI-18 Week 0, Week 6 Week 18
Health status: Rand SF-12 Week 0, Week 6 Week 18
Process measures
Nutritional and Metabolic
Biomarkers
Week 6 Weeks 10, 14,
and 18
Dietary Intake Assessment Week 5-6 Week 16-18
Food Intake Diary 3 days every 4
weeks
BMI, BP, Weight Week 5-6 Weeks 10, 14, and
18
Effect modification measures
Demographics Week 0
Clinical Characteristics Week 0
Expectation of benefit† After dietary
instruction
*International Classification of Headache Disorders, defined by expert
members of the International Headache Society
† Based on a measure developed by Borkovec and Nau to measure credibility
of psychological interventions.
§ Headache Impact Test was developed to measure headache-related quality
of life.
# Migraine disability assessment score assesses the number of days of missed
work or school in the past 3 months.
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they were bothered in the last 7 days by each of 18
symptoms, including separate scores for anxiety,
depression, somatization, and a global symptom
severity index. The BSI has good internal consistency
and test-retest reliabilities (alpha = 0.71-0.85; r =
0.68 - 0.91)[44].
Possible effect modifiers
Effect modifiers consist of demographics and headache-
history variables such as: (1) clinical characteristics of
headache over time; (2) use of prescribed and over-the-
counter medications; (3) associated medical conditions;
(4) family history of headache and other disorders; and
(5) a single-item assessment of satisfaction with care.
Subject credibility and expectations are assessed using
an instrument adapted from a validated scale developed
by Borkovec and Nau [45,46] and administered just
after the first intervention visit. Because high expecta-
tions of treatment are closely related to better outcomes
[47,48], data analysis will test whether participants in
the 2 groups have similar or different expectations of
benefit.
Process Measures
The research dietitian collects a 3-day food record on
visit 3 and daily food-intake checklists every 2 weeks
thereafter. Each week, participants rank their diet adher-
ence on a scale of 1 to 5. The research dietitian rates
diet adherence on a scale of 1 to 5 based on the study-
diet nutrition counseling session every other week. Diet-
ary intake assessments (24-hour recall) are performed
on 3 non-consecutive days during the baseline phase
and repeated during the final 3 weeks of the interven-
tion phase. Blood samples are obtained for fatty acid
analysis at baseline and every 4 weeks during the inter-
vention phase.
Quality control
All personnel complete lab safety training and step-by-
step instruction in lab processing. Research assistants
record the times that the sample is drawn and the time
of each processing step, including the time to centrifuge
and time to freezer (-80 F or liquid N tank) storage
(Eppendorf) tubes. Each specimen is bar-coded, and tri-
ple-recorded to ensure accurate identification. For meta-
bolites sensitive to time, expedited processing ensures
good sample quality.
Adverse events
Reports of adverse events are obtained from participants
at each intervention visit, from self reports recorded in
the headache diaries, or by direct contact via email or
phone with study staff. Adverse events are investigated
by the study neurologist and are reported to the UNC
Institutional Review Board.
Statistical Analysis
Overview
This study is a 2-arm intervention trial with a baseline
measurement and with repeated measures of the out-
come variable over time. The primary outcome variable
is %n-6 in HUFA after dietary interventions. To correct
for violations of the underlying assumptions of regres-
sion (e.g., normality, variance homogeneity), we plan to
use a transformed value of the proportions as our
dependent variable (angular, logit, or power transforma-
tion). We plan to invoke intent-to-treat analysis in deal-
ing with missing data.
Analysis of Aim 1
In Aim 1, we will assess the extent of lowering %n-6 in
HUFA after 12 weeks of targeted dietary interventions. All
participants contribute specimens at randomization (week
6), and at weeks 10, 14 and 18. As a first step, we will test
the equality of the transformed mean proportions after 12
weeks of the intervention with a t-test and will use the
transformed proportions in a regression model to compare
the treatment effects adjusting for covariates, including the
baseline proportion and other variables that may influence
the accumulation and turnover of LA in adipose tissue,
such as age, sex, and baseline BMI.
Analysis of Aim 2
To test Aim 2, we will make use of the repeated measures
of the outcome variable measured at 6, 10, 14, and 18
weeks to compare the rate of reduction in the %n-6 in
HUFA over time in the 2 groups. Because the measure-
ments within each person over time are correlated, we
will use a hierarchical linear model with transformed pro-
portions as the outcome variable. The first-level model
specifies the outcome as a linear function of time. In the
second level, the slope and intercept will be a linear func-
tion of the treatment variable. The random effects will
represent the within- and between-group variances. The
regression coefficients of the time-by-treatment terms
are of interest here. If the regression coefficients of the
interactions are not statistically significant from zero, we
will conclude that the rate of change in the outcome vari-
able over time is the same in both groups.
Secondary Laboratory Aims
The study will explore multiple secondary aims. We will
examine the metabolic impact of dietary interventions
by examining the association between the plasma con-
centrations of n-6 AA-derived mediators and %n-6 in
HUFA. We will employ a mixed model with repeated
measurements of mediators as the outcome and with %
n-6 in HUFA (transformed), time, and time by %n-6 in
HUFA, to formally test the association between the two
variables and the time trends.
We plan to analyze the impact of the dietary interven-
tions on inflammatory gene expression. To estimate
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changes, we will analyze log fold-change as a continuous
response. The hypothesis of no change in mean
response will be tested at the 0.05/80 level, using a
paired t-test, for each of the 84 genes correcting for
multiple comparisons.
Secondary Clinical Aims
We will also examine clinical data, including the diary
data and the HIT-6 score. The 24-hour daily diary, suc-
cessfully used in a previous UNC study, collects hourly
headache experience for 18 weeks [34]. To examine the
role of headache frequency, we will use the diary data to
construct summary measures of headache experience for
each day, including the number of headache hours in a
day and the number of hours with moderate-severe
headaches. With the repeated measurements of head-
ache hours per day as the outcome variable, we will
construct random-effects Poisson regression models
with treatment as the exposure, and age and sex as cov-
ariates, to examine the association between the diets,
blood fatty acids and their derivatives, and headache.
To test the effects on quality-of-life, we will construct
a regression equation with the final HIT-6 score as the
outcome variable, the treatment group as the exposure
variable and the baseline HIT score as the control vari-
able. We will also test a limited number of interaction
effects to see whether the treatment effects vary by sub-
groups (e.g., gender, age). In addition, controlling for
the baseline score, we will examine the relationship
between the post-intervention HIT score and post-inter-
vention %n-6 in HUFA.
Handling of Missing Data
Every effort will be made to contact participants who
fail to complete required study instruments. Based on
our experience with UNC headache patients, we antici-
pate that only a small proportion will not complete the
study. Through missing information evaluation, we will
assess whether drop-outs depend on any patient charac-
teristics. If necessary we will do multiple imputations in
the analysis.
Power calculations
Assuming that the %n-6 in HUFA will be on average
0.8, 0.5 and 0.3 at the end of the 12 weeks (as predicted
by Lands empirical equation [31] and the nutrient intake
targets) and a common standard deviation set at the
maximum value of 0.5, we determined that, to achieve
80% power, we need 32 individuals per each arm.
Repeated measures power-analysis procedures indicate
that we will have adequate power (close to 80%) to test
the time interaction effect with 32 persons measured
over 4 time points (Aim 2).
Results
Recruitment into the study has proceeded as planned
(Table 4). The majority of participants have been
referred by their health care provider, particularly those
who see a neurologist. Other participants are self-
referred, having learned about the study through UNC
advertisements, brochures, flyers, friends and family.
At this time, 124 individuals have been screened for
eligibility of which 63 were enrolled into the study. Five
enrolled individuals were ineligible to begin the dietary
intervention due to low headache frequency (3), an
intervening illness (1), or failure to keep up with the
diaries. In addition to those who did not qualify, 10
individuals withdrew after giving consent, 5 during the
baseline phase and 5 during the diet phase. Of the 5
individuals who withdrew during the baseline phase, 4
cited scheduling difficulties and 1 moved out of town.
Of the 5 individuals who withdrew after randomization,
3 cited difficulty adjusting to the diet, 1 became preg-
nant, and another withdrew due to a traumatic injury
that was unrelated to the study diet.
Adherence with the daily diary has been excellent,
with 83.3% of participants completing at least 80% of
daily entries. Most have tolerated the diets well; they
have demonstrated diet adherence via changes in ery-
throcyte fatty acids. Preliminary analysis of composite
erythrocyte fatty acid data of the first 20 participants,
Table 4 Recruitment for the exploratory analgesic dietary
intervention for chronic daily headache, May 2010
N Percent
Inquiries about study 183
Potentials to be screened 59 32.2
Screened 124 67.8
Eligible, but declined to participate 5 4.0
Ineligible at telephone screen 35 28.2
Headache characteristics 15 42.9
Medical/psychiatric problems 4 11.4
Logistic problems (time/distance) 11 31.4
Dietary Issues 2 5.7
Other/unknown 3 8.6
Scheduled for baseline consent 84 68.3
Ineligible at baseline consent 5 6.0
Eligible at baseline consent 79 94.0
Withdrew/ineligible before randomization 10 11.9
Withdrew after randomization 5 6.0
Awaiting baseline visit 18 14.5
Enrolled 46 37.9
Referral pattern
Health professionals* 126 72.0
Electronic advertisements 32 18.3
Print advertisements 12 6.9
Family/Friends 2 1.1
Prior Study 3 1.7
Unknown 8
* Health professionals that referred patients to the study included
neurologists, family physicians, and nurses.
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with blinding preserved (i.e., both diet groups are ana-
lyzed together and investigators remain masked to diet
group), reveals significant reductions in %n-6 in HUFA
and n-6 AA and LA, and significant increases in n-3
EPA, DHA and the omega-3 index compared with base-
line erythrocyte fatty acids over the 12-week interven-
tion (Table 5).
Based on our current rates of recruitment, we expect
to have a sufficient number of participants to complete
the study 2 1/2 years after the first patient was enrolled.
Based on these numbers, we should have adequate
power to test our hypothesis of differential %n-6 HUFA
in both plasma and erythrocyte lipid pools. Examination
of the clinical data of the study (HIT-6, daily diaries)
should allow us to predict effect sizes for a larger clini-
cal trial.
Discussion
This protocol paper provides a detailed overview of
design and implementation of a randomized, outpatient,
clinical trial comparing two novel analgesic dietary inter-
ventions as a strategy for management of CDH. Results
so far indicate excellent adherence with both diets,
enabled by provision of food for more than 2 meals per
day, expert dietary counseling, and extensive web-based
educational tools to support the interventions. Partici-
pants in the study have demonstrated a willingness to
keep study appointments, adhere to the diets, and com-
plete daily headache diaries. In addition, quality control
procedures have ensured that laboratory specimens are
meeting the highest standards for processing.
Preliminary blinded analysis of erythrocyte fatty acid
data indicates significant reductions in n-6 AA and %n-
6 in HUFA, and significant increases in n-3 EPA, DHA
and the omega-3 index (Table 5). These changes are sta-
tistically significant despite the composite analysis of
both dietary groups, albeit with greater variability than
expected for one diet alone. Importantly, it is not possi-
ble to determine if %n-6 in HUFA and n-6 AA were
reduced in both, or only one, diet group from this
preliminary analysis. It is also worth noting the signifi-
cant reduction of n-6 LA in these first 20 participants.
To our knowledge, this is the first demonstration of
reduced LA in human tissues with dietary LA intake
below 2 en%. Recently, metabolic derivatives of LA,
including 9- and 13-hydroxyoctadecadienoic acid (9-
and 13-HODE), were identified as an endogenous family
of potent TRPV1 (endovanilloid) receptor agonists
[49,50]. TRPV1 receptors are critically involved in the
initiation and perpetuation of chronic pain, and TRPV1
antagonists have potent analgesic effects [51]. Therefore,
the long-term consumption of diets that contain less
than 2 en% as LA could promote analgesia by reducing
the LA content in human tissues and subsequently
down-regulating the synthesis of LA-derived TRPV1
agonists. The long-term consumption of the low n-6,
and low n-6 plus high n-3 diets in our current trial
could have important implications for central pain sensi-
tization and human physical pain via altering the abun-
dance and metabolism of LA, AA, EPA, and/or DHA.
Full analyses of metabolic and clinical outcomes at
study completion will provide novel data to help answer
the following open questions:
1) Does the reduction of dietary n-6 LA and AA
over a 12-week period decrease the abundance of
LA and AA, and increase n-3 EPA and DHA, in
human erythrocytes and plasma?
2) Does the reduction of dietary n-6 LA and AA
decrease circulating levels of bioactive mediators
derived from LA (e.g. endovanilloids) and AA (e.g.
eicosanoids, endocannabinoids)?
3) Does the addition of n-3 ALA, EPA and DHA to
low n-6 diets produce additional metabolic
alterations?
4) Do low n-6, average n-3 diets and/or low n-6,
high n-3 diets attenuate human physical pain? If so,
are pain reductions correlated with alterations in tis-
sue contents of specific fatty acids and/or their
metabolic derivatives?
Table 5 Means of erythrocyte fatty acids over the 12-week intervention, Chronic Daily Headache study, May 2010
Baseline (n = 20) Week 4 (n = 20) Week 8 (n = 20) Week 12 (n = 18)
Variable Mean 95% CI Mean 95% CI Mean 95% CI Mean 95% CI
Omega-3 index 4.4 3.9, 5.0 6.2 5.4, 7.1 7.0 5.9, 8.1 7.8 6.5, 9.0
% n-6 in HUFA* 76.3 74.5, 78.0 70.4 67.5, 73.2 67.4 63.7, 71.0 64.7 60.3, 69.0
DHA 4.0 3.5, 4.5 5.2 4.5, 5.8 5.7 4.9, 6.5 6.3 5.4, 7.3
EPA 0.46 0.39, 0.54 1.1 0.8, 1.3 1.3 0.95, 1.6 1.4 1.0, 1.8
AA 14.8 14.5, 15.2 14.4 13.7, 15.1 13.8 13.2, 14.5 13.7 12.9, 14.5
LA 11.5 10.8, 12.1 9.5 8.8, 10.2 9.3 8.6, 10.0 9.5 8.8, 10.3
* %n-6 in HUFA is the percentage of omega-6 fatty acid in total HUFA as calculated by: 100 × (20:3n-6 + 20:4n-6 + 22:4n-6 + 22:5n-6)/(20:5n-3 + 22:5n-3 + 22:6n-
3 + 20:3n-6 + 20:4n-6 + 22:4n-6 + 22:5n-6 + 20:3n-9).
Abbreviations: HUFA, highly-unsaturated fatty acid; DHA, Docosahexaenoic acid; EPA, eicosapentaenoic acid; AA, arachidonic acid; LA, linoleic acid.
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Limitations
The primary methodological limitation for interpreting
the primary outcome (%n-6 in HUFA) and other meta-
bolic outcomes of this trial is the limited duration of 12
weeks. Industrialized populations consuming large quan-
tities of LA-rich seed oils maintain large quantities of n-
6 LA in adipose tissue. In the US, adipose tissue LA
increased from about 6% of total fatty acids in 1960
[52,53] to about 18% in 1986 [54], which coincided with
an increase in dietary LA from about 2 en% in 1909 to
7 en% in 1999 [55]. Because n-6 and n-3 fatty acids
have a half-life of about 1 to 2 years in adipose tissue
[56-58], the 12-week dietary period employed in this
trial may not be of sufficient duration for plasma and
erythrocyte PUFAs to reach dynamic equilibrium. Our
preliminary blinded analysis of erythrocyte fatty acid
data is consistent with the expectation that maximal
reductions in plasma and tissue LA and/or AA may not
occur over 12 weeks; AA and %n-6 in HUFA continued
to decline, and EPA, DHA, and the omega-3 index con-
tinued to increase between 8 and 12 weeks (Table 5).
The primary methodological limitation for interpreting
the clinical outcomes of this trial is the lack of a control
group consuming average US amounts of individual n-6
and n-3 fatty acids. This will limit the ability to deter-
mine if changes in clinical outcomes (headache fre-
quency, intensity, and quality-of-life) are due to the
diets themselves, to the expectation of benefits asso-
ciated with participation in a clinical trial, or to the pla-
cebo effect of the interventions. This study was not
designed to test the clinical efficacy of the dietary inter-
ventions. However, the study does demonstrate that,
with support, free-living subjects can successfully modify
their diets enough to result in significant changes in ery-
throcyte fatty acids, setting the stage for a larger, fully
powered randomized controlled trial of clinical efficacy
in CDH or another chronic pain population.
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